Sarepta Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
DE
Business Address
215 FIRST STREET, CAMBRIDGE, MA, 02142
Mailing Address
215 FIRST STREET, CAMBRIDGE, MA, 02142
Phone
617-274-4000
Fiscal Year End
1231
EIN
930797222
Financial Overview
FY2025
$235.24M
Net Income
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 13, 2026 | View on SEC |
| 4 Insider stock transaction report | March 13, 2026 | View on SEC |
| 4 Insider stock transaction report | March 13, 2026 | View on SEC |
| 4 Insider stock transaction report | March 13, 2026 | View on SEC |
| 4 Insider stock transaction report | March 13, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
Annual Reports
10-K
March 2, 2026
- Elevidys' successful U.S. launch and strong sales growth, exceeding initial expectations.
- Strategic collaboration with Arrowhead Pharmaceuticals significantly expanding pipeline and therapeutic modalities.
Material Events
8-K
Other
February 25, 2026
High Impact
- Elevidys, the first and only FDA-approved gene therapy for DMD, awaits a critical FDA decision on full approval and label expansion by June 21, 2024.
- Despite missing its primary endpoint in the EMBARK trial, Elevidys has started generating revenue and holds multi-billion dollar sales potential.
Insider Trading
SELL
2 insiders
2 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.